SUMMARY -Although the incidence of ventilator-associated pneumonia (VAP) is very high, there are still many uncertainties about clinical course of VAP among tracheotomized patients. Th e goal of the present study was to determine the impact of tracheotomy on VAP incidence and etiology, as well as outcome of VAP patients with tracheotomy. Th e study was conducted in a 15-bed Surgical and Neurosurgical Intensive Care Unit (ICU), Sestre milosrdnice University Hospital Center in Zagreb, Croatia. Th e study included all patients undergoing only percutaneous tracheotomy during the study period. According to our data, the incidence of VAP among percutaneous tracheotomized patients was 42%, not considering the time between tracheotomy and VAP onset. However, when only patients developing VAP after tracheotomy were taken into account, the incidence of VAP among tracheotomized patients dropped to 8% only. Th e most commonly isolated bacterium was Staphylococcus aureus, accounting for 17 (37%) isolates, followed by Haemophilus infl uenzae, accounting for another 10 (22%) isolates. Th e development of VAP among percutaneously tracheotomized patients was associated with longer total ICU stay (regardless of whether VAP developed before or after tracheotomy), while total duration of mechanical ventilation and mortality rate remained unaff ected.
Introduction
Ventilator associated pneumonia (VAP) is one of the most common infections among Intensive Care Unit (ICU) patients 1 . Although the incidence of VAP is very high, there are still many uncertainties about VAP, inter alia the clinical course of VAP in tracheotomized patients. According to previous studies, the incidence of VAP among tracheotomized patients varies from 6% to 26% 2, 3 . However, many studies failed to specify the time elapsed between tracheotomy and VAP onset. Only a small number of studies explicitly state whether tracheotomy preceded VAP or followed it [4] [5] [6] [7] [8] [9] . Th e goal of the present study was to determine the impact of percutaneous tracheotomy on VAP incidence and etiology, as well as outcome of VAP patients with percutaneous tracheotomy.
Patients and Methods
Th e study was conducted in a 15-bed Surgical and Neurosurgical ICU, Department of Anesthesiology and Intensive Care, Sestre milosrdnice University Hospital Center, Zagreb, Croatia. Th e study was approved by the Hospital Board of Ethics (E.P. number: 35-1/09). Retrospective data were collected from September 2009 to March 2013. Because of the retrospective and observational nature of the study, an informed consent was unnecessary.
Th e study included all patients undergoing only percutaneous tracheotomy during the study period. Table 1 shows patient characteristics established at ICU admission. Study patients were divided into two groups according to development of VAP. Th ose with the diagnosis of VAP were further divided into two subgroups of patients tracheotomized after VAP and those tracheotomized before acquiring VAP; so fi nal analysis included three groups of patients, i.e. VAP before tracheotomy, VAP after tracheotomy, and no VAP.
Th e reasons for ICU admission were medical, trauma without surgery or postoperative care. Th e reasons for mechanical ventilation and tracheotomy are shown in Table 2 .
Ventilator-associated pneumonia is defi ned as a type of nosocomial pneumonia occurring more than 48 hours after intubation and mechanical ventilation (MV) 10 . As for the clinical diagnosis, VAP was established according to the Clinical Pulmonary Infection Score (CPIS), based on six clinical assessments, each worth zero to two points 11 . A score of more than six was considered suggestive of VAP. Th e CPIS score was calculated when there was clinical suspicion of VAP (presence of new or progressive infi ltration on chest radiography and presence of at least two of the following criteria: fever, leukocytosis and purulent tracheal secretion). Only the fi rst VAP episode was evaluated. Quantitative culture of endotracheal aspirate (ETA) was performed to identify VAP pathogens. A pathogen isolated in a concentration of more than 10E5 CFU/mL was considered causative of VAP. Th e ETA sample with more than 10 squamous epithelial cells per visual fi eld was considered as invalid sample 12 . Early-onset VAP was defi ned as that occurring within the fi rst 4 days of MV and late-onset VAP as that occurring after fourth day of MV.
Percutaneous tracheotomy was performed by ICU physicians at patient bedside using Griggs method. Th e reasons for performing tracheotomy are shown in Table 2 . Tracheotomized patients were divided into those tracheotomized during the fi rst 7 days following ICU admission (early tracheotomy) and those tracheotomized 7 or more days after ICU admission (late tracheotomy).
Th e exclusion criteria were pneumonia prior to MV or within 48 hours following MV initiation, tracheotomy performed before ICU admission, emergency tracheotomy and age below 18.
All patients were fed enterally using a nasogastric tube (in most patients starting from the second day of ICU stay), received systematic stress ulcer prophylaxis (ranitidine or proton pump inhibitors) and were kept in a semi-recumbent position during their ICU stay.
Between group comparison was made based on patient status at ICU admission, during ICU stay and at ICU discharge, as well as on the etiology of VAP and characteristics of surviving patients.
Statistical analysis
Data on patient age, APACHE II score, SAPS II and number of reintubations, as well as number of days on MV or number of days of stay in ICU were expressed as median and 25 th -75 th interquartile range, while other data were expressed as number (%). Continuous variables were compared using Kruskal-Wallis ANOVA, while categorical variables were compared using χ 2 -test. Th e values of p<0.05 were considered statistically signifi cant. All statistical analyses were performed using the MedCalc 9.5.1.0 software (MedCalc Software, Mariakerke, Belgium).
Results
During the study period, 5071 adult patients were admitted to our ICU and 142 (2.8%) of them underwent percutaneous tracheotomy. Table 1 shows patient characteristics established at ICU admission. Patient groups did not diff er signifi cantly according to age, gender, APACHE II score and SAPS II, smoking habit and prevalence of the majority of comorbidities, with the exception of diabetes mellitus. Diabetes mellitus was most prevalent in the VAP after T group as compared to the two other groups. Th e proportions of the main reasons for ICU admission were not diff erent among the groups. Th e type of surgical patients did not signifi cantly diff er among the groups. In all groups, postoperative care was the most frequent reason for ICU admission (Table 1) .
Ventilator-associated pneumonia developed in 60 (42%) percutaneously tracheotomized patients, of which 48 (80%) not tracheotomized before VAP onset (VAP before T) and 12 (20%) tracheotomized before VAP onset (VAP after T). Eighty-two (58%) percutaneously tracheotomized patients did not develop VAP during the study period (no VAP). Table 2 shows the characteristics of VAP patients observed during ICU stay. Th e main reason for mechanical ventilation was mostly of respiratory nature in the VAP before T group, the need for sedation and respiratory reasons at a similar rate in the VAP after T group, and all three reasons for MV equally represented in the no VAP group. Patient groups did not diff er signifi cantly according to the number of reintubations, number of patients treated by antibiotics, glucocorticosteroids, sedatives, dialysis or transfusions, reasons for tracheotomy, timing of tracheotomy and number of days on MV before tracheotomy. Th e number of days at ICU before tracheotomy was highest in the VAP before T group as compared to the other two groups. Th e length of ICU stay before VAP development and duration of MV before VAP were longer in the VAP after T group as compared to the VAP before T group.
Fourteen patients were excluded from the analysis of etiology (invalid sample in four, bacterial growth below 10 5 CFU/mL in fi ve, sterile ETA sample in three, and uncollected ETA sample in two patients). So, fi nal analysis of bacterial etiology included 46 patients/ETA samples with 73 bacterial species isolated.
Among 73 isolated bacteria, 52 (71.2%) were gramnegative bacteria (Table 3) . Haemophilus infl uenzae was the most commonly isolated gram-negative bacterium, accounting for 10 (22%) isolates. Th e next most commonly isolated gram-negative bacteria were Pseudomonas aeruginosa and Escherichia coli, each accounting for Results are expressed as median (25 th -75 th interquartile range) or as number (%); ICU = intensive care unit; VAP = ventilator-associated pneumonia; T = (percutaneous) tracheotomy; SAPS II = Simplifi ed Acute Physiology Score II; APACHE II = Acute Physiology and Chronic Health Evaluation II; COPD = chronic obstructive pulmonary disease; * acute respiratory failure, sepsis, state after resuscitation; † neck, thorax, abdomen another 9 (20%) isolates, followed by Acinetobacter species (17%) and Enterobacter species (13%). Th e overall number of gram-positive bacterial species was 21 (28.8%). Table 3 shows that Staphylococcus (S.) aureus was the most commonly isolated gram-positive bacterium. Among all S. aureus isolates, 6 (35.2%) isolates were methicillin resistant S. aureus (MRSA). MRSA was isolated in 4 of 13 (30.8%) S. aureus isolates in the VAP before T group and in 2 of 4 (50%) S. aureus isolates in the VAP after T group (p=0.495). Among all bacteria, the most common cause of VAP was S. aureus, accounting for 17 (37%) of total isolated bacteria. In 12 ETA samples, mixed bacterial and fungal species were isolated. Th ere were 9 Candida species and 3 Aspergillus species isolated. Th ere was no statistically signifi cant diff erence in the etiology between the VAP before T group and VAP after T group (Table 3) . Monomicrobial infection occurred in 27 of 46 (58.7%) patients, and polymicrobial infection in 19 (41.3%) patients, 14 patients of them infected with two pathogens, three with 3 pathogens and two patients with 4 pathogens.
Th e overall ICU mortality among percutaneous tracheotomy patients was 29% (41/142). Mortality Results are expressed as median (25 th -75 th interquartile range) or as number (%); VAP = ventilator-associated pneumonia; T = (percutaneous) tracheotomy; MV = mechanical ventilation; ICU = intensive care unit; *acute respiratory failure, neuromuscular weakness, acute respiratory distress syndrome; † Glasgow Coma Scale (GCS) lower than 9;
‡ predicted long MV due to trauma or disease of the lung (>10 days), weaning diffi culties, neuromuscular weakness/need for frequent suctioning (>10-12 times daily); § GCS lower than 9; # during fi rst seven days after admission to ICU; **from day 8 of ICU admission was not diff erent among the groups (35% vs. 25% vs. 26%, p=0.467) ( Table 2) .
Survival did not diff er signifi cantly among patient groups according to any variable observed at ICU admission and during ICU stay, except for the prevalence of diabetes mellitus (Tables 4 and 5 ). Diabetes mellitus was most prevalent in the VAP after T group as compared to the two other groups.
In surviving patients, total number of days in ICU was shorter in the no VAP group as compared to the other two groups. Th e length of ICU stay before VAP was shorter in the VAP before T group as compared to the VAP after T group. Th e number of days at ICU before tracheotomy was higher in the VAP before T group as compared to the other two groups. Th e length of ICU stay after tracheotomy was shorter in the no VAP group as compared to the other two groups. Duration of MV before VAP was longer in the VAP after T group as compared to the VAP before T group, and duration of MV after VAP was longer in the VAP before T group as compared to the VAP after T group. Survival did not diff er signifi cantly according to the number of ICU day s after VAP, total duration of mechanical ventilation, duration of MV before tracheotomy, duration of MV after tracheotomy and SAPS II at discharge (Table 6 ).
Discussion
Based on our results, the prevalence of percutaneous tracheotomy in ICU patients was 2.8%. It is a relatively low percentage as compared to the results of other studies 8, [13] [14] [15] [16] [17] , but the number of percutaneous tracheotomies performed at our ICU has been constantly increasing (from 32 in 2010 to 54 in 2012).
During the study period, the incidence of VAP among percutaneously tracheotomized patients was Results are expressed as number of bacterial species isolates (% of the number of ETA samples); VAP = ventilator--associated pneumonia; ETA = endotracheal aspirate 42% (60/142). According to recent literature, the incidence of VAP among tracheotomized patients varies from 6% to 26% 2, 3 , but can be much higher, especially in surgical ICUs 18 . Th erefore, the high rate of VAP found in our surgical ICU is in line with these data. Also, prior antibiotic administration is a VAP risk factor too 18 , and almost all our patients were receiving antibiotics. Th e use of antibiotics may partly explain the higher incidence of VAP recorded in our study. However, many studies have failed to specify the time elapsed from tracheotomy to VAP onset. Only a small number of studies explicitly state whether tracheotomy preceded VAP or followed it [4] [5] [6] [7] [8] [9] . To this matter, the work by Nseir et al. even warns that the incidence of VAP after tracheotomy has never been compared with the incidence before tracheotomy or the incidence in patients without tracheotomy 4 . Pawar et al. found that the majority of VAP cases (88.9%) occur before tracheotomy, so that tracheotomy comes as a result of VAP rather than posing a risk factor for its development 6 . According to our data, the incidence of VAP among tracheotomized patients was 42%, the time elapsed from tracheotomy to VAP onset not being considered. However, when only patients developing VAP after tracheotomy were taken into account, the incidence of VAP among tracheotomized patients dropped to 8% (12/142) only.
To the best of our knowledge, our study was the fi rst to identify diabetes mellitus as a risk factor for VAP-after-T development. Univariate analysis showed diabetes mellitus to be most prevalent in the VAP after T arm. Whether diabetes mellitus really is a risk factor for VAP development is hard to tell because of the small number of patients in the VAP after T arm. Some studies found diabetes mellitus to be more common among VAP patients 19, 20 , whereas others report that diabetes mellitus does not pose a risk factor for VAP onset 21 . In the VAP before T arm, the main reason for starting MV was of respiratory nature, whereas in the VAP after T arm MV was introduced due to the need of sedation, as well as for respiratory reasons (both grounds for MV initiation, thereby being represented in similar rates). In the no VAP group, all of the above grounds for MV introduction were equally represented. Th e possible reasons behind the earlier VAP development witnessed in the VAP before T arm could be respiratory tract-related, whereas VAP seen in the VAP after T arm it could have been the result of prolonged ICU stay and prolonged MV, the latter being known as a risk factor favoring VAP development. Namely, the length of pre-VAP ICU stay and the length of pre-VAP MV were proven to be statistically signifi cantly shorter in the VAP before T as compared to the VAP after T arm, both when it comes to all patients under study and the surviving patients only. Th e afore-mentioned fi ndings lead to a conclusion that VAP seen in the VAP before T arm could mostly be characterized as an early-developing one. Numerous researches conducted insofar have shown early-emerging VAP to be associated with lower mortality rates, shorter MV duration and shorter ICU stay 22 . However, our data indicated the mortality rates to be equal in the two arms, while MV duration and ICU stay length both turned out to be shorter in the VAP before T, i.e. in the early VAP arm. In surviving patients, post-VAP MV and post-VAP ICU stay were proven to be shorter in the VAP after T, i.e. in the late VAP arm. Th e most probable reason for the shorter MV and shorter ICU stay seen across the above study arm is the fact Results are expressed as median (25 th -75 th interquartile range) or as number (%); VAP = ventilator-associated pneumonia; T = (percutaneous) tracheotomy; MV = mechanical ventilation; ICU = intensive care unit; *acute respiratory failure, neuromuscular weakness, acute respiratory distress syndrome; † Glasgow Coma Scale (GCS) lower than 9;
‡ predicted long MV due to trauma or disease of the lung (>10 days), weaning diffi culties, neuromuscular weakness/need for frequent suctioning (>10-12 times daily); § GCS lower than 9; # during fi rst seven days after admission to ICU; **from day 8 of ICU admission Results are expressed as median (25 th -75 th interquartile range) or as number (%); VAP = ventilator-associated pneumonia; T = (percutaneous) tracheotomy; MV = mechanical ventilation; ICU = intensive care unit; SAPS II = Simplifi ed Acute Physiology Score II that, at the VAP nascence time-point, most of the patients assigned to that study group had already been tracheotomized, thus tracheotomy being a contributor to earlier weaning from MV and subsequently also to shorter ICU stay. Th e study by Nseir et al. showed lower mortality rates in early VAP-developing patients 4 , but some of the prospective studies failed to confi rm the above results [23] [24] [25] . Many studies compared the impact of early versus late tracheotomy in terms of the ability to reduce MV duration and length of ICU stay. According to many prospective randomized studies, early tracheotomy seems to reduce the duration of MV and the length of ICU stay [26] [27] [28] [29] . However, a few recent meta-analyses failed to confi rm any favorable impact of early tracheotomy on MV duration and length of ICU stay 30 . According to our results, the duration of pre-tracheotomy MV was similar in all study arms. Also, weaning from MV took place at a similar post-tracheotomy time point, suggesting that tracheotomy itself rather than its timing was the critical factor responsible for the duration of post-tracheotomy MV. Th e length of pretracheotomy ICU stay was proven longer in the VAP before tracheotomy arm as compared to other study arms, so that VAP before tracheotomy patients could be classifi ed as those having late tracheotomy, while members of the other study groups could be classifi ed as those having early tracheotomy. Th e length of posttracheotomy ICU stay was shorter in the no VAP group as compared to other study arms. Th ese data suggest that early tracheotomy is associated with a reduced length of post-tracheotomy ICU stay, but only in patients that did not develop VAP.
Ventilation-associated pneumonia is associated with high mortality rates. According to our data, mortality rates recorded in our study patients did not diff er among the study arms (35% vs. 25% vs. 25%; p=0.467) ( Table 2) . Th e all-cause mortality recorded among percutaneously tracheotomized patients was 29% (41/142). Th is percentage is similar to the VAP mortality rate reported in the literature 3, 8 . Some studies found increased mortality rates in VAP patients 5, 6, 31 , whereas others failed to demonstrate any impact of VAP on the mortality rate 3, 32 . A case-control study that included 85 VAP patients well matched with 85 controls has reported a VAP mortality rate of 40% and non-VAP mortality rate of 38.8%, that is to say, there was no statistically signifi cant between-group diff erence 32 . Neither did Rello et al. establish a signifi cantly higher mortality rate among VAP as compared to VAP-free patients 3 . Causal relationship between high VAP mortality and VAP itself has been a subject of debate, some thereby perceiving VAP simply as a sign of general downhill course witnessed in seriously ill patients. Th ese observations may indicate that, in critically ill patients, host factors and underlying diseases are more important outcome determinants than either the microorganisms responsible for VAP development or the treatments administered. Based on our results, mortality rate seen in the VAP before T arm was higher than that observed in the VAP after T and no VAP arms (35% vs. 25%), although the diff erence was not statistically signifi cant. Since shortening of MV duration, tracheotomy may have contributed to faster patient recovery and lower mortality, although the contribution was obviously not statistically signifi cant. In their retrospective study that included more than 9000 patients, Rello et al. found no diff erence in mortality rates between patients with and without VAP 33 . Earlier reports pointed to gram-negative bacteria as the most common VAP-causative agent 34 . In our study, 52 (71.2%) VAP cases were caused by gramnegative bacteria, which is in line with the results of similar studies, in which approximately 60% of VAPcausing bacteria were found to be gram-negative
However, judging by our data, the most commonly isolated species was the gram-positive bacterium strain Staphylococcus aureus, accounting for 36% of VAP before T and 40% of VAP after T cases. According to Park et al., one of the risk factors for the development of VAP caused by Staphylococcus aureus is a neurosurgical procedure justifying ICU admission 35 , and our study arm constituted of percutaneously tracheotomized patients included 107 (75%) neurosurgical patients. Th e etiologic backgrounds were similar across the study arms, their similarity thereby being a possible reason for the similarity of mortality rates recorded in each study arm 1 . In 30%-50% of cases, VAP has been reported to be a polymicrobial infection, the reported rates thereby diff ering based on the diagnostic method used 1 . In our patients, polymicrobial VAP genesis was confi rmed in 41.3% of cases.
Total MV duration has often been tagged as a risk factor facilitating VAP development 1 ; nevertheless, it should not be perceived as such, although it is truly longer in VAP patients, just because of the VAP itself, i.e development of VAP is the cause of prolonged MV. Only the occurrence precedent to VAP, and not one emerging post VAP, can be perceived as a VAP risk factor, so that only the duration of pre-VAP MV rather than total MV duration should be seen as a VAP risk factor. On top of that, post-VAP MV duration should be analyzed solely in surviving patients, since the only reason for shorter MV duration in some of eventually departed patients is the fatal outcome itself. Based on our data, total MV duration recorded across the surviving VAP and VAP-free patients does not differ at all.
We also found that patients having developed VAP stayed longer at ICU than those free from VAP. Similar results concerning the relevance of ICU stay length for VAP patients have also been reported elsewhere 6 . Our results also suggest the length of ICU stay among percutaneously tracheotomized VAP patients to be similar regardless of whether VAP developed before or after tracheotomy.
In conclusion, the development of VAP among percutaneously tracheotomized patients was associated with longer total ICU stay (regardless of whether VAP developed before or after tracheotomy), while total duration of MV and mortality rate remained unaff ected.
Our study had some limitations in terms of retrospective and observational nature, heterogeneity of reasons for ICU admission, single ICU coverage and small sample size, especially when it comes to the VAP after T arm.
